SMALL CAP IDEA: Allergy Therapeutics transformation has redefined its trajectory Allergy Therapeutics is writing a story of resilience and transformation.
Its pioneering short-course therapies, designed to tackle conditions such as hay fever and peanut allergy, promise not only to disrupt traditional treatments but to drive significant growth and value in the process.
Historically, Allergy Therapeutics has operated in a niche market, relying on the 'named patient' model - a system in which bespoke treatments are prescribed under regulatory exemptions.
In the second half of the financial year, the company posted its first revenue growth since 2021, a milestone that signals progress but also serves as a prelude to something potentially transformative.
That journey has already begun with the Grass MATA MPL treatment - for grass pollen allergies - which late last month was submitted for regulatory approval in Germany.
